| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/21/2006 | US7014858 Orally administering, especially by sustained release, a tetracycline compound or salt in a sub-bactericidal amount that that reduces telangiectasiais but has no antibiotic activity |
| 03/21/2006 | US7014856 for stimulating or enhancing production of an antibody which recognizes a ganglioside; comprises a ganglioside or oligosaccharide portion conjugated to an immunogenic protein with a carrier and/or vehicle; cancer treatment |
| 03/21/2006 | US7014852 Alkaline phosphatase to induce weight loss or to reduce weight gain |
| 03/21/2006 | US7014846 polyallylamine hydrochloride crosslinked with epichlorohydrin; phosphate removal from gastrointestinal tract; hyperphosphatemia; side effect reduction |
| 03/21/2006 | US7014845 copolymer of a polysaccharide and a vinyl or acrylic polymer crosslinked with a diamine, amino acid or polypeptide; sustained release; as the polysaccharide is degraded by intestinal bacteria, an active steroidal or nonsteroidal drug is released for effective absorption |
| 03/21/2006 | US7014841 Delivery of antiemetics through an inhalation route |
| 03/21/2006 | US7014840 heating a thin coating to form a vapor then allowing to cool to form a condensation aerosol; kits |
| 03/21/2006 | US7014796 Irradiation with microwaves |
| 03/21/2006 | US7014781 Methods and articles for maintaining hydantoinylated polymers in a biocidally active state |
| 03/21/2006 | US7014652 Methods for treating prostatitis |
| 03/21/2006 | CA2521933C Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
| 03/21/2006 | CA2506238A1 Chroman derived compounds & formulations thereof for use in therapy |
| 03/21/2006 | CA2443314C Method of imaging cell death in vivo |
| 03/21/2006 | CA2399358C Pyrrole substituted 2-indolinone protein kinase inhibitors |
| 03/21/2006 | CA2315220C Integrin receptor antagonists |
| 03/21/2006 | CA2282254C Hydroxyazepanes as inhibitors of glycosidase and hiv protease |
| 03/21/2006 | CA2270887C Methods and compositions for inhibition of angiogenesis |
| 03/21/2006 | CA2267251C Novel phenoxyethylamine derivatives, method of preparation, application as medicine and pharmaceutical compositions containing same |
| 03/21/2006 | CA2263983C Cyclic amine derivatives for inhibiting blood platelet aggregation |
| 03/21/2006 | CA2245647C Novel bridged cyclic amino acids as pharmaceutical agents |
| 03/21/2006 | CA2244418C Methods for embolizing blood vessels |
| 03/21/2006 | CA2244140C Alkylated styrenes as prodrugs to cox-2 inhibitors |
| 03/21/2006 | CA2242416C Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same |
| 03/21/2006 | CA2238816C N-acyl-2-substituted-4-(benzimidazolyl- or imidazopyridinyl-substituted residues)-piperidines as tachykinin antagonists |
| 03/21/2006 | CA2193703C Protein kinase c inhibitors |
| 03/21/2006 | CA2193551C Eliminating agent for activated oxygen and free radicals |
| 03/21/2006 | CA2189863C Mucoadhesive emulsions containing cyclodextrin |
| 03/21/2006 | CA2183250C Prodrugs of morpholine tachykinin receptor antagonists |
| 03/21/2006 | CA2178949C Morpholine and thiomorpholine tachykinin receptor antagonists |
| 03/21/2006 | CA2177955C Use of dimeticone for treating constipation |
| 03/21/2006 | CA2147854C Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them |
| 03/21/2006 | CA2139112C Novel nicotinic acid esters |
| 03/21/2006 | CA2135535C Medicinal formulations containing thioctic acid or dihydrolipoic acid in the form of inclusion compounds with cyclodextrins or cyclodextrin derivatives and in the form of granulates, chewable or effervescent tablets |
| 03/21/2006 | CA2133998C Treatment of macular degeneration |
| 03/21/2006 | CA2129771C Phenylalkanolamine derivatives |
| 03/21/2006 | CA2124932C Sex steroid activity inhibitors |
| 03/21/2006 | CA2072416C Cyclopropenone derivatives |
| 03/21/2006 | CA2071415C Low micron-sized ascorbic acid particles, especially a suspension thereof in a medium in which they are insoluble, and the use thereof as an antioxidant for mediums in which the particles remain insoluble |
| 03/21/2006 | CA2062792C Treatment of androgen-related diseases |
| 03/20/2006 | WO2006102191A1 Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors |
| 03/20/2006 | CA2600175A1 Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors |
| 03/17/2006 | CA2482039A1 Method of attenuating graft rejection |
| 03/17/2006 | CA2477867A1 Peptides, dna's, rna's, and compounds for inhibiting or inducing adrenomedullin activity, and use of the same |
| 03/16/2006 | WO2006029385A2 Quinazoline derivatives as metabolically inert antifolate compounds. |
| 03/16/2006 | WO2006029371A2 Neuromedin u 2 receptor agonists and uses thereof |
| 03/16/2006 | WO2006029349A1 Combination of organic compounds |
| 03/16/2006 | WO2006029319A2 Modulating phosphatase activity in cardiac cells |
| 03/16/2006 | WO2006029255A2 Cationic antiseptic compositions and methods of use |
| 03/16/2006 | WO2006029245A2 Compositions and methods relating to novel compounds and targets thereof |
| 03/16/2006 | WO2006029223A2 Method for stimulating the immune response of newborns |
| 03/16/2006 | WO2006029213A2 Silver dihydrogen citrate compositions |
| 03/16/2006 | WO2006029210A2 Acyclic 1,3-diamines and uses therefor |
| 03/16/2006 | WO2006029209A2 Method for activating trpv4 channel receptors by agonists |
| 03/16/2006 | WO2006029189A2 Topical medicament |
| 03/16/2006 | WO2006029167A2 Treatment of diseases using nalmefene and its analgos |
| 03/16/2006 | WO2006029155A2 Improved ghb compositions |
| 03/16/2006 | WO2006029154A2 Novel compounds |
| 03/16/2006 | WO2006029146A2 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS |
| 03/16/2006 | WO2006029142A2 Methods and systems for treating asthma and other respiratory diseases |
| 03/16/2006 | WO2006029115A2 2-amino 1h imidazo ring systems and methods |
| 03/16/2006 | WO2006029081A2 Nucleoside-lipid conjugates, their method of preparation and uses thereof |
| 03/16/2006 | WO2006029075A2 Fibrate compounds having ppar agonist activity |
| 03/16/2006 | WO2006029040A2 Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof |
| 03/16/2006 | WO2006029036A2 Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
| 03/16/2006 | WO2006029013A2 Topical dermatological formulations and use thereof |
| 03/16/2006 | WO2006028970A1 Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases |
| 03/16/2006 | WO2006028969A1 Pancreatic cancer treatment using na+/k+ atpase inhibitors |
| 03/16/2006 | WO2006028962A2 1-alkoxy 1h-imidazo ring systems and methods |
| 03/16/2006 | WO2006028961A2 Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators |
| 03/16/2006 | WO2006028958A2 Pyridyl inhibitors of hedgehog signalling |
| 03/16/2006 | WO2006028957A1 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| 03/16/2006 | WO2006028948A2 Use of methyl pyruvate or methyl pyruvic acid for the treatment of diseases of the nervous system and for protecting a human central nervous system against neuronal degeneration caused by defective intracellular energy production |
| 03/16/2006 | WO2006028939A1 Controlled and directed local delivery of anti-inflammatory compositions |
| 03/16/2006 | WO2006028904A1 Quinazolines useful as modulators of ion channels |
| 03/16/2006 | WO2006028875A1 Phenanthridine carbonyl phenols as cytokine modulators |
| 03/16/2006 | WO2006028836A1 Wound healing |
| 03/16/2006 | WO2006028835A2 Use of thyroid hormone conversion inhibitors |
| 03/16/2006 | WO2006028831A2 Compositions comprising 5-amino-2-hydroxybenzoic acid and a reducing sugar |
| 03/16/2006 | WO2006028830A2 Opioid dosage forms having dose proportional steady state cave and auc and less than dose proportional single dose cmax |
| 03/16/2006 | WO2006028810A2 Method of wound healing using a2b adenosine receptor antagonists |
| 03/16/2006 | WO2006028635A2 Fullerene compositions for ameliorating hearing loss, collateral damage of chemotherapy, or mucositis |
| 03/16/2006 | WO2006028631A2 Inhibition of voluntary ethanol consumption with non-peptidyl melanocortin 4-receptor agonists |
| 03/16/2006 | WO2006028618A1 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
| 03/16/2006 | WO2006028590A1 1,1,2,2-tetra (hetero) arylethanes or 1,1,2-tri (hetero) aryl-2-heterocyclylethanes as potassium channel inhibitors |
| 03/16/2006 | WO2006028545A2 Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
| 03/16/2006 | WO2006028525A2 [3.2.0] heterocyclic compounds and methods of using the same |
| 03/16/2006 | WO2006028524A2 Compositions and treatments for inhibiting kinase and/or hmg-coa reductase |
| 03/16/2006 | WO2006028361A1 Implants and microspheres for the sustained release of drugs for ophthalmic use and preparation methods thereof |
| 03/16/2006 | WO2006028290A1 2-morpholino-4-pyrimidone compound |
| 03/16/2006 | WO2006028284A1 Morpholine compound |
| 03/16/2006 | WO2006028270A1 Rebamipide preparation for rectal administration to be prepared before using |
| 03/16/2006 | WO2006028269A2 Thiazole derivatives having vap-1 ihibitory activity |
| 03/16/2006 | WO2006028239A1 Carbamoyl-substituted spiro derivative |
| 03/16/2006 | WO2006028226A1 Novel imidazolidine derivative and use thereof |
| 03/16/2006 | WO2006028161A1 Serotonin 5-ht3 receptor agonist |
| 03/16/2006 | WO2006028160A1 S-oligonucleotide conjugate and antisense agent |
| 03/16/2006 | WO2006028122A1 Agent for preventing and ameliorating obesity |
| 03/16/2006 | WO2006028120A1 Preventive/remedy for obesity |
| 03/16/2006 | WO2006028110A1 Process for producing water-soluble hyaluronic acid modification |
| 03/16/2006 | WO2006028038A1 Sulfonamide derivative selectively inhibiting mmp-13 |